Okava Pharmaceuticals has launched MEOW-1, a trial of a microchip-sized implant that releases a GLP-1 drug over three months to treat obesity in cats. The randomized study will enroll 50 cats and monitor safety and weight-loss outcomes for six months. If successful, Okava plans to seek FDA approval in 2027–2028 and later explore a similar option for dogs; estimated cost is about $100 per month.
MEOW-1 Trial Tests Microchip-Sized GLP-1 Implant to Reduce Obesity in Cats
04:46 AM, 12/06/2025
Similar Articles
Daily Oral GLP‑1 Pill Cuts About 10% of Body Weight in 18 Months, Study Finds
Trial results: Orforglipron, an investigational oral GLP‑1, produced about 10% average body‑weight loss after 72 weeks in adu...
States Pull Back Medicaid Coverage for GLP-1 Weight-Loss Drugs as Costs Bite
Many states are cutting or tightening Medicaid coverage for GLP-1 weight-loss drugs amid rising costs and federal policy chan...
WHO: Weight‑loss Injections Can Help — But They Won’t Solve the Global Obesity Crisis
The WHO says injectable GLP‑1 drugs (liraglutide, semaglutide, tirzepatide) can support weight loss in adults but are not a s...
This Week in Science: Oral Ozempic Alternative, Insulin Skin Cream, Mars Meteorite and More
This week’s highlights: orforglipron, an oral small-molecule candidate, produced dose-dependent weight loss comparable to inj...
NIH Approved $1.7M in New and Extended Cat Experiments Despite Pledge to Phase Them Out, Watchdog Says
Key points: Documents from White Coat Waste show the NIH awarded more than $1.7 million in new and extended grants for cat ex...
Low-dose Ozempic-like Drug Produces ‘Younger’ Molecular Profile in Mice — Human Effects Unknown
Researchers treated middle-aged mice with low-dose exenatide, a GLP-1 receptor agonist similar in action to semaglutide, for ...
Needle-Free Ozempic? Daily Semaglutide Pill Nearly Matches Wegovy Injection in Major Trial
Bottom line: A 71-week, double-blind trial of 307 participants found a once-daily 25 mg oral semaglutide pill produced an ave...
Intermittent Energy Restriction Rapidly Alters Gut Microbiome and Brain Activity During Weight Loss
In a 62-day study of 25 people with obesity, an intermittent energy restriction (IER) diet led to average weight loss of 7.6 ...
Gut Microbe and Its Metabolite May Trigger an Ozempic‑Like GLP‑1 Response — A Potential Natural Way to Curb Sugar Cravings
Researchers at Jiangnan University report that the gut bacterium Bacteroides vulgatus and one of its metabolites increased GL...
US FDA to Scale Back Primate Use in Some Drug Safety Tests
The U.S. Food and Drug Administration has reportedly told drugmakers it will stop requiring laboratory monkeys for certain dr...
Tirzepatide Quieted 'Food Noise' in a Brain-Recorded Case — Effect Wore Off After Several Months
This small brain-recording case followed a 60-year-old woman with obesity and loss-of-control eating who was taking tirzepati...
Metformin’s Brain Link: Study Shows Rap1 in the Ventromedial Hypothalamus Is Required for Its Glucose-Lowering Effect in Mice
The study in Science Advances shows that metformin reaches the ventromedial hypothalamus and suppresses a brain protein calle...
After 60 Years, Metformin Found to Act Directly on the Brain — Mouse Study Reveals New Pathway
Researchers report that metformin reaches the ventromedial hypothalamus (VMH) in mice and suppresses the Rap1 protein, improv...
Two FDA-Approved Cancer Drugs, Combined, Reduce a Key Alzheimer’s Protein in Mice — 1.4M Health Records Helped Point the Way
UCSF researchers used gene-expression screening and 1.4 million anonymized health records to repurpose existing drugs for Alz...
Goodbye to Finger Pricks: MIT’s Light-Based Glucose Monitor Shrinks Toward Watch Size
MIT researchers report progress on a noninvasive, light-based glucose monitor that could replace finger pricks and implanted ...